West Pharmaceutical Services - WST Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $435.20
  • Forecasted Upside: 22.62%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$354.91
▼ -3.38 (-0.94%)

This chart shows the closing price for WST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New West Pharmaceutical Services Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for WST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for WST

Analyst Price Target is $435.20
▲ +22.62% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for West Pharmaceutical Services in the last 3 months. The average price target is $435.20, with a high forecast of $536.00 and a low forecast of $375.00. The average price target represents a 22.62% upside from the last price of $354.91.

This chart shows the closing price for WST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in West Pharmaceutical Services. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/29/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2024UBS GroupLower TargetNeutral ➝ Neutral$400.00 ➝ $375.00Low
2/13/2024KeyCorpBoost TargetOverweight ➝ Overweight$440.00 ➝ $470.00Low
2/7/2024Jefferies Financial GroupUpgradeHold ➝ Buy$323.00 ➝ $536.00Low
10/27/2023StephensLower TargetOverweight ➝ Overweight$420.00 ➝ $390.00Low
8/30/2023KeyCorpBoost TargetOverweight ➝ Overweight$415.00 ➝ $440.00Low
8/21/2023KeyCorpBoost TargetOverweight ➝ Overweight$385.00 ➝ $415.00Low
7/28/2023KeyCorpBoost TargetOverweight$375.00 ➝ $385.00Low
7/17/2023StephensBoost Target$400.00 ➝ $420.00Low
6/16/2023Bank of AmericaUpgradeNeutral ➝ Buy$390.00 ➝ $405.00Low
4/11/2023StephensUpgradeEqual Weight ➝ Overweight$330.00 ➝ $400.00Low
2/22/2023Deutsche Bank AktiengesellschaftBoost Target$250.00 ➝ $290.00Low
2/17/2023KeyCorpBoost TargetOverweight$315.00 ➝ $375.00Low
12/13/2022Deutsche Bank AktiengesellschaftInitiated CoverageHold$250.00Low
12/2/2022KeyCorpLower TargetOverweight$350.00 ➝ $315.00Low
11/30/2022UBS GroupInitiated CoverageNeutral$250.00Low
10/28/2022Bank of AmericaDowngradeBuy ➝ Neutral$385.00 ➝ $250.00Low
10/28/2022KeyCorpLower TargetOverweight$400.00 ➝ $350.00Low
2/22/2022William BlairReiterated RatingOutperformHigh
7/30/2021KeyCorpBoost TargetOverweight$350.00 ➝ $475.00High
11/9/2020KeyCorpInitiated CoverageOverweight$350.00High
10/13/2020StephensInitiated CoverageEqual Weight$300.00High
7/21/2020Bank of AmericaUpgradeNeutral ➝ Buy$280.00Low
4/24/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$145.00 ➝ $200.00High
12/12/2019Bank of AmericaDowngradeNeutral ➝ Underperform$135.00Medium
7/26/2019Bank of AmericaUpgradeUnderperform ➝ NeutralHigh
5/1/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$122.00Medium
4/23/2019William BlairInitiated CoverageOutperform ➝ Outperform$112.16Medium
(Data available from 2/28/2019 forward)

News Sentiment Rating

0.79 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 24 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/2/2023
  • 15 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/1/2023
  • 15 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2023
  • 16 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/31/2023
  • 10 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/30/2023
  • 16 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2023
  • 20 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 35 very positive mentions
  • 33 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
2/28/2024

Current Sentiment

  • 35 very positive mentions
  • 33 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
West Pharmaceutical Services logo
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Read More

Today's Range

Now: $354.91
Low: $352.65
High: $359.95

50 Day Range

MA: $362.97
Low: $338.27
High: $413.00

52 Week Range

Now: $354.91
Low: $309.43
High: $415.73

Volume

141,002 shs

Average Volume

572,622 shs

Market Capitalization

$26.01 billion

P/E Ratio

45.04

Dividend Yield

0.22%

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of West Pharmaceutical Services?

The following equities research analysts have issued reports on West Pharmaceutical Services in the last year: Bank of America Co., Jefferies Financial Group Inc., KeyCorp, Stephens, StockNews.com, and UBS Group AG.
View the latest analyst ratings for WST.

What is the current price target for West Pharmaceutical Services?

5 Wall Street analysts have set twelve-month price targets for West Pharmaceutical Services in the last year. Their average twelve-month price target is $435.20, suggesting a possible upside of 21.5%. Jefferies Financial Group Inc. has the highest price target set, predicting WST will reach $536.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $375.00 for West Pharmaceutical Services in the next year.
View the latest price targets for WST.

What is the current consensus analyst rating for West Pharmaceutical Services?

West Pharmaceutical Services currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for WST.

What other companies compete with West Pharmaceutical Services?

Other companies that are similar to West Pharmaceutical Services include ResMed, Baxter International, Insulet, Teleflex and Shockwave Medical. Learn More about companies similar to West Pharmaceutical Services.

How do I contact West Pharmaceutical Services' investor relations team?

West Pharmaceutical Services' physical mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier's listed phone number is (610) 594-2900 and its investor relations email address is [email protected]. The official website for West Pharmaceutical Services is www.westpharma.com. Learn More about contacing West Pharmaceutical Services investor relations.